Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149990 | 0.84 | HPGD (0.61) | HPGDLMNAHTTSMN1; SMN2CA2 | |
| SCHEMBL1421898 | 0.84 | HPGD (0.65) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL27953074 | 0.82 | CA2 (0.52) | CA2 | |
| SCHEMBL16799573 | 0.81 | HPGD (0.61) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL398078 | 0.79 | HPGD (0.57) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL7861945 | 0.79 | HPGD (0.67) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL12309811 | 0.77 | HPGD (0.77) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL28195310 | 0.77 | PPARA (0.55) | SMN1; SMN2CA2 | |
| Hydrochloric Acid SCHEMBL4640605 | 0.77 | HPGD (0.69) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL8068242 | 0.77 | CA2 (0.53) | LMNAMAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | claimed |
| EP-1984370-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-29 | — | — | EP | claimed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | claimed |
| WO-2015083130-A1 | FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015083130-A1 | FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-11 | — | — | WO | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| EP-1984370-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | HPGD 3447/4885LMNA 1495/4885HTT 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.